Literature DB >> 6287293

Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin.

G E Gillies, E A Linton, P J Lowry.   

Abstract

Initially the hypothalamic factor responsible for the release of corticotropin (CRF), was thought to be a simple peptide. More recent work has led to the conclusion that CRF is a multifactorial complex. In 1979 we proposed that vasopressin, much disputed as a CRF candidate, was a major constituent of the complex, interacting with a potentiating the CRF activity of the other component(s). The recent characterization of a 41 residue ovine hypothalamic peptide capable of releasing adrenocorticotropic hormone (ACTH) in a dose-related manner has allowed us to compare its CRF bioactivity with that of vasopressin and simple extracts of the hypothalamus, and to investigate any interaction it may have with vasopressin and other hypothalamic factors in the release of ACTH. We report here that the new CRF is more potent than vasopressin in releasing ACTH. When given simultaneously with vasopressin a fourfold potentiation of CRF activity with steep dose-response characteristics were observed. It also potentiated vasopressin-free hypothalamic extracts, suggesting that a new CRF does not account for all the nonvasopressin portion of the CRF complex.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287293     DOI: 10.1038/299355a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  134 in total

Review 1.  Aspects of anterior pituitary growth, with special reference to corticotrophs.

Authors:  A M McNicol; E Carbajo-Perez
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

Review 2.  Childhood abuse and migraine: epidemiology, sex differences, and potential mechanisms.

Authors:  Gretchen E Tietjen; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

3.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

4.  Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary. A possible model for human multiple endocrine neoplasia type 1.

Authors:  D Murphy; A Bishop; G Rindi; M N Murphy; G W Stamp; J Hanson; J M Polak; B Hogan
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

Review 5.  Vasopressin and alcohol: a multifaceted relationship.

Authors:  Kathryn M Harper; Darin J Knapp; Hugh E Criswell; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2018-11-03       Impact factor: 4.530

Review 6.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

7.  Intracerebroventricular administration of atrial natriuretic peptide prevents increase of plasma ADH, aldosterone and corticosterone levels in restrained conscious dehydrated rabbits.

Authors:  C Kallaras; N Angelopoulos; S Bountzioukas; K Mavroudis; M Karamouzis; O Guiba-Tziampiri
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

8.  Corticotrophin-releasing factor, vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the rat.

Authors:  S L Lightman; W S Young
Journal:  J Physiol       Date:  1988-09       Impact factor: 5.182

Review 9.  Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans.

Authors:  Claire-Dominique Walker; Sophie Deschamps; Karine Proulx; Mai Tu; Camilla Salzman; Barbara Woodside; Sonia Lupien; Nicole Gallo-Payet; Denis Richard
Journal:  J Psychiatry Neurosci       Date:  2004-09       Impact factor: 6.186

Review 10.  Role of interleukin-1 in stress responses. A putative neurotransmitter.

Authors:  F Shintani; T Nakaki; S Kanba; R Kato; M Asai
Journal:  Mol Neurobiol       Date:  1995-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.